SENSIENT TECHNOLOGIES CORP

SXT
About the company

Sensient Technologies Corporation, together with its subsidiaries, manufactures and markets colors, flavors, and other specialty ingredients worldwide. It operates in three segments: Flavors & Extracts, Color, and Asia Pacific. The Flavors & Extracts segment develops, manufactures, and supplies flavor systems for the food, beverage, and personal care industries under the Sensient Flavors and Sensient Agricultural Ingredients brands.

Country: United StatesPrice: $116.70Market Cap: $5.0B

Investment snapshot

35%positive consensus
Scored 1d ago

Positive

6

BUY / PASS

Neutral / negative

3 / 7

NEUTRAL / FAIL

Median fair value

$40.46

-65.3% vs price

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictNEUTRALPASSFAILFAIL · Rank #1340 (Top 43.3%)PASSPASSFAILFAILFAILFAILPASSNEUTRALPASSBUYFAILNEUTRALFAIL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/A
Margin of Safety-160.8%-188.4%-810.3%-239.2%N/A-180.9%-1100.6%-402.2%-84.8%-182.5%-742.0%-169.0%N/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-13

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-30

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-10-30

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS42.1x
      ✗Graham<= 15x
      Price-to-Book Ratio4.1x
      ✗Graham<= 1.5x
      P/E x P/B174.60
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)9.10
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value4.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=4.4%, ROC=16.7%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS36.9x
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)38.7x
      ✗Dreman< 8x
      Price / Book Value per Share4.1x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessP/E=36.9x, OE Yield=2.1%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldP/E=36.9x, FCF Yield=0.8%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/E=36.9x, P/B=4.1x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value-180.9% (IV=$41.55 vs Price=$116.70)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share128.8x
      ✗Ackman<= 25
      Price vs. Trailing Low168% of trailing low ($69.40)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization+3.41%; #2241/6340 (top 35.3%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.2591; #3886/6449 (top 60.3%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS36.9x
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E0.15
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share6.65x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change+27.7%
      ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.3518; #3105/5247 (top 59.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-0.35%; #2593/4519 (top 57.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+25.27%; #1158/6202 (top 18.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Valuation models0% pass✗ 11▾

      SXT overvalued: all 11 models price fair value below $116.70 (median $40.46)

      Graham fair value$44.74
      ✗Graham-160.8% margin vs $116.70
      Buffett fair value$40.46
      ✗Buffett-188.4% margin vs $116.70
      Lynch fair value$12.82
      ✗Lynch-810.3% margin vs $116.70
      Greenblatt fair value$34.40
      ✗Greenblatt-239.2% margin vs $116.70
      Dreman fair value$41.55
      ✗Dreman-180.9% margin vs $116.70
      Munger fair value$9.72
      ✗Munger-1100.6% margin vs $116.70
      Pabrai fair value$23.24
      ✗Pabrai-402.2% margin vs $116.70
      Akre fair value$63.15
      ✗Akre-84.8% margin vs $116.70
      Marks fair value$41.31
      ✗Marks-182.5% margin vs $116.70
      Ackman fair value$13.86
      ✗Ackman-742.0% margin vs $116.70
      Templeton fair value$43.38
      ✗Templeton-169.0% margin vs $116.70
    • Profitability25% pass✓ 17✗ 18▾

      12 of 16 flag SXT's profitability — Buffett, Lynch, Greenblatt +9 more

      Positive EPS (10 years)18/18 years positive
      ✓GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)42.3%
      ✓Graham>= 33% growth
      Net Income Positive (10+ years)18/18 years positive
      ✓BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)11.7%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)12.8% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$124.5M
      ✓BuffettPositive and growing
      Earnings Variance (10-yr CoV)0.23
      ✓BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)9.10
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR4.1%
      ✓Lynch15-30% (Fast Grower); > 0% to pass
      ROE13.2%
      ✗Lynch> 15%
      EBIT / Enterprise Value4.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=4.4%, ROC=16.7%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets5.99%
      ✓PiotroskiROA > 0
      ROA Change YoY6.16% -> 5.99% (delta: -0.17%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=5.70%, ROA=5.99%
      ✗PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY32.6% -> 33.5%
      ✓PiotroskiImproved YoY
      Pre-Tax Income / Revenue12.7%
      ✓Dreman>= 8%
      Net Income / Shareholders' Equity13.2%
      ✓Dreman> 12%
      Margin of SafetyP/E=36.9x, P/B=4.1x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity10.6% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value-180.9% (IV=$41.55 vs Price=$116.70)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency18/18 years positive
      ✓MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue14.5%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity13.2%
      ✗Ackman>= 15%
      5-Year EPS CAGR4.1% CAGR over 5 years
      ✓Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend10.6% (2023) -> 12.8% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 31.6% -> 33.5%, operating margin 10.6% -> 12.8%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization+3.41%; #2241/6340 (top 35.3%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+24.03%; #1789/3702 (top 48.3%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity+13.16%; #1353/5226 (top 25.9%)
      ✓AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0086; #734/5884 (top 12.5%)
      ✓AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR4.1% over 5 years
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years10/10 years positive
      ✓Schloss>= 70% positive over 5-10 observed years (app rule)
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag SXT's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio3.97
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)8.8%
      ✗Buffett> 10%
      ROIC - WACC-1.2%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)16.7%
      ✗Greenblatt> 25%
      Current Ratio Change YoY3.55 -> 4.10
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.77x -> 0.72x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities3.97
      ✓Dreman> 1.5
      Return on Invested Capital9.7%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=7.2%; FY2024: ROIC=8.9%; FY2025: ROIC=8.6%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC5.7% (RR=59% x ROIC=9.7%)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest 8.6%)
      ✗SleepROIC > 12% in a majority of years
    • Cash Flow30% pass✓ 4✗ 8▾

      7 of 10 flag SXT's cash flow — Lynch, Piotroski, Dreman +4 more

      Free Cash Flow Proxy$124.5M
      ✓BuffettPositive and growing
      FCF Positive and Growing$-17.5M
      ✗LynchPositive and growing
      Operating Cash Flow$127.8M
      ✓PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=5.70%, ROA=5.99%
      ✗PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)38.7x
      ✗Dreman< 8x
      P/E or FCF YieldP/E=36.9x, FCF Yield=0.8%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive16/18 years FCF positive
      ✓MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-0.4%
      ✗Ackman>= 4%
      Price / FCF per Share128.8x
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency18/18 years positive
      ✓SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-17.5M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-0.35%; #2593/4519 (top 57.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth38% pass✓ 6✗ 7▾

      5 of 8 flag SXT's growth — Lynch, Dreman, Ackman +2 more

      EPS Growth (3-yr avg, 10-yr window)42.3%
      ✓Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)9.10
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR4.1%
      ✓Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 21.0% vs Rev: 9.5%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction$1.89 (2008) -> $3.16 (2025)
      ✓DremanPositive over recent years
      EPS CAGR3.1% CAGR over 17 years
      ✗Dreman> 5% annualized
      Positive Net Income Frequency18/18 years positive
      ✓MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth3.5%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency4/5 years with positive EPS growth
      ✓AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR4.1% CAGR over 5 years
      ✓Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 31.6% -> 33.5%, operating margin 10.6% -> 12.8%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR3.9%
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR4.1% over 5 years
      ✗Neff7%-20% annualized
    • Verdicts43% pass✓ 6✗ 8▾

      Split decision: 7 FAIL · 5 PASS · 3 NEUTRAL · 1 BUY

      Overall verdict
      •GrahamNEUTRAL (6/9)✓BuffettPASS (4/9)✗LynchFAIL (1/7)✗GreenblattRank #1340✓PiotroskiPASS (F-Score 4)✓DremanPASS (6/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (3/5)✓AckmanPASS (4/9)•TempletonNEUTRAL (5/8)✓SleepPASS (3/6)✓AsnessBUY (Rank #603/2370 (Top 25.4%))✗NeffFAIL (2/6)•SchlossNEUTRAL (5/7)✗OshaughnessyFAIL (Rank #654/963 (Top 67.9%))
    • Debt & Leverage50% pass✓ 8✗ 7▾

      6 of 12 pass — Buffett, Lynch, Piotroski +3 more object

      LT Debt vs Net Current AssetsLT Debt $790.1M vs NCA $959.6M
      ✓GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.61, IC: 8.0x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.61
      ✗Lynch< 0.33
      Cash - Long-term Debt$-747.5M
      ✗LynchPositive preferred
      LT Debt / Total Assets Change30.32% -> 31.60%
      ✗PiotroskiDecreased YoY
      Current Assets / Current Liabilities3.97
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0.61
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Debt Levels0.61
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=8.0x, D/EBITDA=2.5x
      ✓MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.61
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.6143; #2690/4210 (top 63.9%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Chemicals
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Mid Cap($5.0B)
    Revenue: $1.6B+3.5% YoY
    Net Income: $134.5M+7.9% YoY

    Financial Snapshot

    Operating Margin12.8%
    Return on Equity11.3%
    Debt / Equity0.59
    Current Ratio4.10
    EPS (Diluted)$3.16+7.5% 1y
    Shares Retired−0.2% / −0.4% 2y

    Shareholder Return

    Fiscal 2025

    Issued 0.2% of shares last year, 0.4% issued over two.

    Buybacks
    —
    Dividends
    $69.6M

    What drove EPS

    A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

    FY22
    18.9% = 18.6% + 0.2%
    FY23
    −33.8% = −33.7% + −0.2%
    FY24
    33.0% = 33.5% + −0.3%
    FY25
    7.5% = 7.9% + −0.4%
    Earnings Fewer shares More shares

    Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, dividends paid.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex, dividends paid.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex, dividends paid.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-02-13
    FY 2024
    Sources
    • 10-K · 2025-02-19
    FY 2023
    Sources
    • 10-K · 2024-02-22
    FY 2022
    Sources
    • 10-K · 2023-02-17
    FY 2021
    Sources
    • 10-K · 2022-02-18
    Market Cap$5.0Bcurrent------$4.0Best.$3.1Best.$2.5Best.$3.0Best.$3.2Best.
    Revenue$1.7B↑10%$455.8M↑11%$462.1M↑12%$435.8M↑11%$1.6B↑4%$1.6B↑7%$1.5B↑1%$1.4B↑4%$1.4B
    Operating Income$254.1M↑20%$72.4M↑26%$76.7M↑33%$66.7M↑25%$207.1M↑8%$191.6M↑24%$155.0M↓21%$196.8M↑16%$170.0M
    Net Income$169.4M↑22%$48.3M↑31%$51.4M↑37%$44.2M↑28%$134.5M↑8%$124.7M↑33%$93.4M↓34%$140.9M↑19%$118.7M
    EPS (Diluted)--$1.13↑30%$1.20↑36%$1.04↑28%$3.16↑7%$2.94↑33%$2.21↓34%$3.34↑19%$2.81
    Gross Margin————33.5%↑3%32.6%↑3%31.6%↓7%34.0%↑3%32.9%
    Operating Margin14.5%↑10%15.9%↑14%16.6%↑19%15.3%↑12%12.8%↑4%12.3%↑16%10.6%↓22%13.7%↑11%12.3%
    ROE13.2%↑12%———11.3%↓4%11.8%↑33%8.9%↓37%14.1%↑11%12.7%
    Total Debt$790.4M↑11%$790.4M↑11%$763.9M↑4%$767.8M↑9%$709.6M↑12%$633.4M↓4%$658.5M↑1%$650.7M↑27%$511.5M
    Shareholders' Equity$1.3B↑9%$1.3B↑9%$1.3B↑9%$1.2B↑11%$1.2B↑12%$1.1B↑1%$1.1B↑5%$999.6M↑7%$938.4M
    Current Ratio3.97↓14%3.97↓14%4.39↑3%5.01↑16%4.10↑15%3.55↓10%3.96↑15%3.43↑8%3.19
    Debt / Equity0.61↑2%0.61↑2%0.61↓5%0.63↓2%0.590.60↓5%0.63↓4%0.65↑19%0.55
    Operating Cash Flow$119.9M↑15%$40.5M↓8%$48.5M-$13.6M↓52%$127.8M↓19%$157.2M↓7%$169.7M↑1306%$12.1M↓92%$145.2M
    Free Cash Flow-$17.5M↓174%$2.2M↓91%$9.7M↓64%-$42.4M↓64%$38.4M↓61%$97.9M↑20%$81.8M↑222%-$67.3M↓180%$84.4M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Chemicals

    SXT vs Peers — Financial Grading

    Revenue$1.6BBottom 25%
    Net Income$134.5MMedian
    ROE11.3%Median
    D/E0.59Median
    Op. Margin12.8%Median
    Curr. Ratio4.10Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    EIDP, Inc.CTA-PB$46.8B$54.21——————2/95/92/70/3F-Score 14/11
    INTERNATIONAL FLAVORS & FRAGRANCES INCIFF$20.3B$81.16$10.9B$359.0M-2.5%0.42-3.5%1.423/90/92/70/3F-Score 63/11
    CF Industries Holdings, Inc.CF$18.3B$125.09$7.1B$1.8B37.2%0.6632.5%3.373/94/95/73/3F-Score 88/11
    RPM INTERNATIONAL INC/DE/RPM$13.2B$103.73$7.9B$661.4M20.0%0.77—1.683/92/93/71/3F-Score 67/11
    Element Solutions IncESI$8.0B$33.08$2.6B$190.8M7.1%0.6113.4%3.682/92/91/71/3F-Score 56/11
    NEWMARKET CORPNEU$6.5B$709.19$2.7B$418.7M23.5%0.5020.0%2.534/96/92/71/3F-Score 55/11
    HEXCEL CORP /DE/HXL$6.0B$79.46$1.9B$109.4M8.7%0.799.1%2.262/92/93/70/3F-Score 64/11
    ICL Group Ltd.ICL$5.8B$4.52$7.2B$226.0M3.8%0.468.1%1.335/94/92/70/3F-Score 45/11